# US 2015/0148759 A1 · Pharmaceutical Patch for Transdermal Administration of Tapentadol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148759 A1
- Document ID: US20150148759A1
- Status: Published application
- Kind: A1
- Application number: 14/597,789
- Filed: 2015-01-15
- Published: 2015-05-28
- Earliest claimed: 2012-07-16
- Assignees: Gruenenthal GmbH
- Applicants: Gruenenthal GmbH
- Inventors: Ingo FRIEDRICH; Martin MIKYNA; Sandra GEDAT
- Web page: https://patentgrep.com/patent/US20150148759A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 9/7061: {Polyacrylates}
- A61K 9/7069: {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.

## Claims

### Claim 1

A pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising
a) a surface layer,
b) an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and
c) a removable protective layer,
wherein the adhesive layer is located between the surface layer and the removable protective layer.

### Claim 2 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the adhesive layer comprises an acrylate-, silicone- or styrene block copolymer-based pressure sensitive adhesive.

### Claim 3 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the pressure sensitive adhesive contains a polymer which is derived from a monomer composition comprising monomer units having at least one hydroxyl functional group.

### Claim 4 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the concentration of the pharmacologically active ingredient in the adhesive layer is within the range of from 1 to 1,500 g/m2 and/or within the range of from 1 to 20 wt.-%, relative to the total weight of the adhesive layer.

### Claim 5 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the pharmacologically active ingredient is Tapentadol in form of its free base.

### Claim 6 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the adhesive layer comprises an acrylate-based pressure sensitive adhesive.

### Claim 7 (depends on 6)

The pharmaceutical patch according to claim 6, wherein the adhesive layer comprises a copolymer comprising monomer units originating from monomers A which are selected from C1-18-alkyl (meth)acrylates and/or monomers B which are copolymerizable with monomers A.

### Claim 8 (depends on 7)

The pharmaceutical patch according to claim 7, wherein
(i) monomers A are selected from the group consisting of methyl (meth)acrylate, ethyl (meth)acrylate, propyl (meth)acrylate, butyl (meth)acrylate, pentyl (meth)acrylate, hexyl (meth)acrylate, cyclohexyl (meth)acrylate, octyl (meth)acrylate, isobornyl (meth)acrylate, and mixtures thereof; and/or
(ii) monomers B are selected from the group consisting of 2-hydroxyethyl (meth)-acrylate, glyceryl mono(meth)acrylate, glycidyl (meth)acrylate, acrylamide, N,N-diethyl(meth)acrylamide, 2-ethoxyethyl (meth)acrylate, 2-ethoxyethoxyethyl (meth)acrylate, tetrahydrofuryl (meth)acrylate, vinyl acetate, N-vinyl pyrrolidone and mixtures thereof.

### Claim 9 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the adhesive layer comprises a silicone-based pressure sensitive adhesive.

### Claim 10 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the adhesive layer comprises a styrene block copolymer-based pressure sensitive adhesive, e.g. a styrene-butadiene-styrene block copolymer.

### Claim 11 (depends on 1)

The pharmaceutical patch according to claim 1, wherein the adhesive layer comprises a permeation component which enhances permeation of the pharmacologically active ingredient through human skin.

### Claim 12 (depends on 11)

The pharmaceutical patch according to claim 11, wherein the relative weight ratio of the pharmacologically active ingredient to the permeation component is within the range of from 1,000:1 to 1:1,000.

### Claim 13 (depends on 11)

The pharmaceutical patch according to claim 11, wherein the permeation component comprises an alcohol and/or a fatty acid and/or a fatty acid ester.

### Claim 14 (depends on 13)

The pharmaceutical patch according to claim 13, wherein the alcohol is dodecanol, the fatty acid is oleic acid and the fatty acid ester is isopropyl myristate or sorbitan monostearate.

### Claim 15 (depends on 1)

The pharmaceutical patch according to claim 1, which upon application to the human skin provides release of the pharmacologically active ingredient at a rate of at least 1.0 μg·cm−2·h−1 over a period of at least 6 hours.
